Clinical sub-phenotypes of Staphylococcus aureus bacteraemia
Maaike C Swets,Zsuzsa Bakk,Annette C Westgeest,Karla Berry,George Cooper,Wynne Sim,Rui Shian Lee,Tze Yi Gan,William Donlon,Antonia Besu,Emily Heppenstall,Luke Tysall,Simon Dewar,Mark de Boer,Vance G Fowler,David H Dockrell,Guy E Thwaites,Miquel Pujol,Natàlia Pallarès,Cristian Tebé,Jordi Carratalà,Alexander Szubert,Geert H Groeneveld,Clark D Russell
DOI: https://doi.org/10.1093/cid/ciae338
IF: 20.999
2024-06-27
Clinical Infectious Diseases
Abstract:Background Staphylococcus aureus bacteraemia (SAB) is a clinically heterogeneous disease. The ability to identify sub-groups of patients with shared traits (sub-phenotypes) is an unmet need that could allow patient stratification for clinical management and research. We aimed to test the hypothesis that clinically-relevant sub-phenotypes can be reproducibly identified amongst patients with SAB. Methods We studied three cohorts of hospitalised adults with monomicrobial SAB: a UK retrospective observational study (Edinburgh cohort, n=458), the UK ARREST randomised trial (n=758), and the Spanish SAFO randomised trial (n=214). Latent class analysis was used to identify sub-phenotypes using routinely-collected clinical data, without considering outcomes. Mortality and microbiologic outcomes were then compared between sub-phenotypes. Results Included patients had predominantly methicillin-susceptible SAB (1366/1430,95.5%). We identified five distinct, reproducible clinical sub-phenotypes: (A) SAB associated with older age and comorbidity, (B) nosocomial intravenous catheter-associated SAB in younger people without comorbidity, (C) community-acquired metastatic SAB, (D) SAB associated with chronic kidney disease, and (E) SAB associated with injection drug use. Survival and microbiologic outcomes differed between the sub-phenotypes. 84-day mortality was highest in sub-phenotype A, and lowest in B and E. Microbiologic outcomes were worse in sub-phenotype C. In a secondary analysis of the ARREST trial, adjunctive rifampicin was associated with increased 84-day mortality in sub-phenotype B and improved microbiologic outcomes in sub-phenotype C. Conclusions We have identified reproducible and clinically-relevant sub-phenotypes within SAB, and provide proof-of-principle of differential treatment effects. Through clinical trial enrichment and patient stratification, these sub-phenotypes could contribute to a personalised medicine approach to SAB.
immunology,infectious diseases,microbiology